Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,127 | 240 | 1,865 |
| Samples | 794 | 123 | 665 |
| Peptides | 634 | 88 | 553 |
Function
MET · MET proto-oncogene, receptor tyrosine kinase
This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000397752 | P08581 | 873 | 612 |
| ENST00000318493 | P08581-2 | 809 | 586 |
| ENST00000436117 | P08581-3 | 443 | 331 |
| ENST00000422097 | A0ACM8QMG8* | 2 | 2 |
Gene Properties
Recurrent Mutations
All 612 amino-acid changes on canonical ENST00000397752 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MET · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MET – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 18/133 14% |
| Endometrial Carcinoma | 8/42 19% | 42/612 7% |
| Melanoma | 9/210 4% | 113/1899 6% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 33/1390 2% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 2/71 3% |
| Other Solid Cancers | 3/94 3% | 39/1515 3% |
| Bladder Carcinoma | 0/58 0% | 26/956 3% |
| Colorectal Carcinoma | 19/143 13% | 65/3239 2% |
| Other Sarcomas | 2/69 3% | 17/699 2% |
| Gastric Carcinoma | 2/74 3% | 33/1809 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Kidney Carcinoma | 2/85 2% | 34/1862 2% |
| Adrenocortical Carcinoma | 0/3 0% | 2/112 2% |
| Glioma | 2/52 4% | 35/2127 2% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
| Rhabdomyosarcoma | 2/33 6% | 1/171 1% |
| Osteosarcoma | 2/45 4% | 1/166 1% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 7/810 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 10/752 1% |
| Hepatocellular Carcinoma | 2/46 4% | 26/2210 1% |
| Neuroendocrine Tumour | 3/154 2% | 6/577 1% |
| Biliary Tract Carcinoma | 1/54 2% | 11/950 1% |
| Ovarian Carcinoma | 2/109 2% | 11/998 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Prostate Carcinoma | 1/13 8% | 21/2105 1% |
| Esophageal Carcinoma | 1/23 4% | 7/769 1% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 19/2550 1% |
| Cervical Carcinoma | 2/35 6% | 2/422 0% |
Mutation Distribution
Where MET is mutated · all tissues, split by cell line vs tissue
How many mutations in MET were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,127 mutations in MET
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|